246 related articles for article (PubMed ID: 37527933)
1. Rapid Characterization of the Functional and Pharmacological Consequences of Cantú Syndrome K
Gao J; McClenaghan C; Matreyek KA; Grange DK; Nichols CG
J Pharmacol Exp Ther; 2023 Sep; 386(3):298-309. PubMed ID: 37527933
[TBL] [Abstract][Full Text] [Related]
2. Kir6.1-dependent K
Davis MJ; Kim HJ; Zawieja SD; Castorena-Gonzalez JA; Gui P; Li M; Saunders BT; Zinselmeyer BH; Randolph GJ; Remedi MS; Nichols CG
J Physiol; 2020 Aug; 598(15):3107-3127. PubMed ID: 32372450
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic Acid Blocks Overactive Kir6.1/SUR2-Dependent K
Scala R; Maqoud F; McClenaghan C; Harter TM; Perrone MG; Scilimati A; Nichols CG; Tricarico D
Cells; 2023 Mar; 12(6):. PubMed ID: 36980269
[TBL] [Abstract][Full Text] [Related]
4. Cantu syndrome-associated SUR2 (ABCC9) mutations in distinct structural domains result in K
McClenaghan C; Hanson A; Sala-Rabanal M; Roessler HI; Josifova D; Grange DK; van Haaften G; Nichols CG
J Biol Chem; 2018 Feb; 293(6):2041-2052. PubMed ID: 29275331
[TBL] [Abstract][Full Text] [Related]
5. Effects of ZD0947, a novel and potent ATP-sensitive K
Mori K; Yamashita Y; Teramoto N
Eur J Pharmacol; 2016 Nov; 791():773-779. PubMed ID: 27693800
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular consequences of KATP overactivity in Cantu syndrome.
Huang Y; McClenaghan C; Harter TM; Hinman K; Halabi CM; Matkovich SJ; Zhang H; Brown GS; Mecham RP; England SK; Kovacs A; Remedi MS; Nichols CG
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089727
[TBL] [Abstract][Full Text] [Related]
7. Kir6.1 and SUR2B in Cantú syndrome.
McClenaghan C; Nichols CG
Am J Physiol Cell Physiol; 2022 Sep; 323(3):C920-C935. PubMed ID: 35876283
[TBL] [Abstract][Full Text] [Related]
8. Differential mechanisms of Cantú syndrome-associated gain of function mutations in the ABCC9 (SUR2) subunit of the KATP channel.
Cooper PE; Sala-Rabanal M; Lee SJ; Nichols CG
J Gen Physiol; 2015 Dec; 146(6):527-40. PubMed ID: 26621776
[TBL] [Abstract][Full Text] [Related]
9. Cantú syndrome resulting from activating mutation in the KCNJ8 gene.
Cooper PE; Reutter H; Woelfle J; Engels H; Grange DK; van Haaften G; van Bon BW; Hoischen A; Nichols CG
Hum Mutat; 2014 Jul; 35(7):809-13. PubMed ID: 24700710
[TBL] [Abstract][Full Text] [Related]
10. Conserved functional consequences of disease-associated mutations in the slide helix of Kir6.1 and Kir6.2 subunits of the ATP-sensitive potassium channel.
Cooper PE; McClenaghan C; Chen X; Stary-Weinzinger A; Nichols CG
J Biol Chem; 2017 Oct; 292(42):17387-17398. PubMed ID: 28842488
[TBL] [Abstract][Full Text] [Related]
11. Potassium channel openers require ATP to bind to and act through sulfonylurea receptors.
Schwanstecher M; Sieverding C; Dörschner H; Gross I; Aguilar-Bryan L; Schwanstecher C; Bryan J
EMBO J; 1998 Oct; 17(19):5529-35. PubMed ID: 9755153
[TBL] [Abstract][Full Text] [Related]
12. Glibenclamide reverses cardiovascular abnormalities of Cantu syndrome driven by KATP channel overactivity.
McClenaghan C; Huang Y; Yan Z; Harter TM; Halabi CM; Chalk R; Kovacs A; van Haaften G; Remedi MS; Nichols CG
J Clin Invest; 2020 Mar; 130(3):1116-1121. PubMed ID: 31821173
[TBL] [Abstract][Full Text] [Related]
13. A Cantú syndrome mutation produces dual effects on KATP channels by disrupting ankyrin B regulation.
Crespo-García T; Rubio-Alarcón M; Cámara-Checa A; Dago M; Rapún J; Nieto-Marín P; Marín M; Cebrián J; Tamargo J; Delpón E; Caballero R
J Gen Physiol; 2023 Jan; 155(1):. PubMed ID: 36287534
[TBL] [Abstract][Full Text] [Related]
14. Myorelaxant action of fluorine-containing pinacidil analog, flocalin, in bladder smooth muscle is mediated by inhibition of L-type calcium channels rather than activation of KATP channels.
Philyppov IB; Golub AА; Boldyriev OI; Shtefan NL; Totska K; Voitychuk OI; Shuba YM
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):585-92. PubMed ID: 26976335
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of KATP channels to cellular metabolic disorders and the underlying structural basis.
Li CG; Cui WY; Wang H
Acta Pharmacol Sin; 2016 Jan; 37(1):134-42. PubMed ID: 26725741
[TBL] [Abstract][Full Text] [Related]
16. Phenylephrine preconditioning in embryonic heart H9c2 cells is mediated by up-regulation of SUR2B/Kir6.2: A first evidence for functional role of SUR2B in sarcolemmal KATP channels and cardioprotection.
Jovanović S; Ballantyne T; Du Q; Blagojević M; Jovanović A
Int J Biochem Cell Biol; 2016 Jan; 70():23-8. PubMed ID: 26556311
[TBL] [Abstract][Full Text] [Related]
17. A key role for the subunit SUR2B in the preferential activation of vascular KATP channels by isoflurane.
Fujita H; Ogura T; Tamagawa M; Uemura H; Sato T; Ishida A; Imamaki M; Kimura F; Miyazaki M; Nakaya H
Br J Pharmacol; 2006 Nov; 149(5):573-80. PubMed ID: 17001304
[TBL] [Abstract][Full Text] [Related]
18. Sulphonylurea receptor 2B and Kir6.1 form a sulphonylurea-sensitive but ATP-insensitive K+ channel.
Yamada M; Isomoto S; Matsumoto S; Kondo C; Shindo T; Horio Y; Kurachi Y
J Physiol; 1997 Mar; 499 ( Pt 3)(Pt 3):715-20. PubMed ID: 9130167
[TBL] [Abstract][Full Text] [Related]
19. ATP-sensitive K(+) channels in rat colonic epithelium.
Pouokam E; Bader S; Brück B; Schmidt B; Diener M
Pflugers Arch; 2013 Jun; 465(6):865-77. PubMed ID: 23262522
[TBL] [Abstract][Full Text] [Related]
20. Characterization of K(ATP)-channels in rat basilar and middle cerebral arteries: studies of vasomotor responses and mRNA expression.
Jansen-Olesen I; Mortensen CH; El-Bariaki N; Ploug KB
Eur J Pharmacol; 2005 Oct; 523(1-3):109-18. PubMed ID: 16226739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
